复发高级别胶质瘤的诊断和治疗

doi:10.3760/cma.j.issn.1673-422X.2017.10.011

摘要/Abstract

摘要： 高级别胶质瘤是一种常见的侵袭性极高的恶性脑肿瘤，而且普遍存在初次治疗后进展和极高的死亡率。早期诊断肿瘤复发及选择高度个体化的治疗对于延长患者生存期有重要意义。多模态磁共振及分子影像学在鉴别诊断胶质瘤复发、预后评估等方面具有重要价值。再手术、再放疗、电场治疗、化疗、靶向治疗、免疫治疗等局部、全身治疗策略有望为复发高级别胶质瘤患者带来生存获益。

关键词: 神经胶质瘤, 复发, 高级别

Abstract: High grade glioma is a kind of malignant brain tumor with strong invasiveness, which progresses commonly after initial treatments and shows high mortality. Early diagnosis of tumor recurrence and highlyindividualized systemic treatment mean significance to prolong survival. Multimode magnetic resonance imaging and molecular imaging play important roles in differential diagnosis and prognosis evaluation for recurrence. Therapeutic strategies like reoperation, reirradiation, electric field technology, chemotherapy, targeted therapies and immunotherapeutic approaches are expected to bring survival benefits for patients with recurrent high grade glioma.

Key words: Glioma, Recurrence, Highgrade

刘雪,任庆兰. 复发高级别胶质瘤的诊断和治疗[J]. 国际肿瘤学杂志, 2017, 44(10): 767-770.

Liu Xue, Ren Qinglan. Diagnosis and treatment of recurrent high grade glioma[J]. Journal of International Oncology, 2017, 44(10): 767-770.

参考文献

［1］ Zhou X, Liao X, Zhang B, et al. Recurrence patterns in patients with highgrade glioma following temozolomidebased chemoradiotherapy［J］. Mol Clin Oncol, 2016, 5(2): 289294. DOI: 10.3892/mco.2016.936. ［2］ Virga J, Bognár L, Hortobágyi T, et al. Tumor grade versus expression of invasionrelated molecules in astrocytoma［J］. Pathol Oncol Res, 2017, In press. DOI: 10.1007/s1225301701946. ［3］ Sanghvi D. Posttreatment imaging of highgrade gliomas［J］. Indian J Radiol Imaging, 2015, 25(2): 102108. DOI: 10.4103/09713026.155829. ［4］ Fatterpekar GM, Galheigo D, Narayana A, et al. Treatmentrelated change versus tumor recurrence in highgrade gliomas: a diagnostic conundrumuse of dynamic susceptibility contrastenhanced (DSC) perfusion MRI［J］. AJR Am J Roentgenol, 2012, 198(1): 1926. DOI: 10.2214/AJR.11.7417. ［5］ Garcia JR, Cozar M, Baquero M, et al. The value of 11Cmethionine PET in the early differentiation between tumour recurrence and radionecrosis in patients treated for a highgrade glioma and indeterminate MRI［J］. Rev Esp Med Nucl Imagen Mol, 2017, 36(2): 8590. DOI: 10.1016/j.remn.2016.06.002. ［6］ Lucas JT Jr, Serrano N, Kim H, et al. 11CMethionine positron emission tomography delineates noncontrast enhancing tumor regions at high risk for recurrence in pediatric highgrade glioma［J］. J Neurooncol, 2017, 132(1): 163170. DOI: 10.1007/s110600162354z. ［7］ Fleischmann DF, Unterrainer M, Bartenstein P, et al. 18FFET PET prior to recurrent highgrade glioma reirradiationadditional prognostic value of dynamic timetopeak analysis and early static summation images?［J］. J Neurooncol, 2017, 132(2): 277286. DOI: 10.1007/s1106001623668. ［8］ Chen MW, Morsy AA, Liang S, et al. Redo craniotomy for recurrent grade Ⅳ glioblastomas: impact and outcomes from the national neuroscience institute singapore［J］. World Neurosurg, 2016, 87: 439445. DOI: 10.1016/j.wneu.2015.10.051. ［9］ Chowdhary SA, Ryken T, Newton HB. Survival outcomes and safety of carmustine wafers in the treatment of highgrade gliomas: a metaanalysis［J］. J Neurooncol, 2015, 122(2): 367382. DOI: 10.1007/s1106001517242. ［10］ Pinzi V, Orsi C, Marchetti M, et al. Radiosurgery reirradiation for highgrade glioma recurrence: a retrospective analysis［J］. Neurol Sci, 2015, 36(8): 14311440. DOI: 10.1007/s1007201521727. ［11］ Conti A, Pontoriero A, Arpa D, et al. Efficacy and toxicity of CyberKnife reirradiation and "dose dense" temozolomide for recurrent gliomas［J］. Acta Neurochir (Wien), 2012, 154(2): 203209. DOI: 10.1007/s0070101111841. ［12］ Shi W, Palmer JD, WernerWasik M, et al. Phase Ⅰ trial of panobinostat and fractionated stereotactic reirradiation therapy for recurrent high grade gliomas［J］. J Neurooncol, 2016, 127(3): 535539. DOI: 10.1007/s1106001620593. ［13］ Kleinberg LR, Stieber V, Mikkelsen T, et al. Outcome of adult brain tumor consortium (ABTC) prospective dosefinding trials of I125 balloon brachytherapy in highgrade gliomas: challenges in clinical trial design and technology development when MRI treatment effect and recurrence appear similar［J］. J Radiat Oncol, 2015, 4(3): 235241. DOI: 10.1007/s135660150210y. ［14］ Schwartz C, Romagna A, Thon N, et al. Outcome and toxicity profile of salvage lowdoserate iodine125 stereotactic brachytherapy in recurrent highgrade gliomas［J］. Acta Neurochir (Wien), 2015, 157(10): 17571764. DOI: 10.1007/s0070101525501. ［15］ Perry JR, Bélanger K, Mason WP, et al. Phase Ⅱ trial of continuous doseintense temozolomide in recurrent malignant glioma: RESCUE study［J］. J Clin Oncol, 2010, 28(12): 20512057. DOI: 10.1200/JCO.2009.26.5520. ［16］ Egan G, Cervone KA, Philips PC, et al. Phase Ⅰ study of temozolomide in combination with thiotepa and carboplatin with autologous hematopoietic cell rescue in patients with malignant brain tumors with minimal residual disease［J］. Bone Marrow Transplant, 2016, 51(4): 542545. DOI: 10.1038/bmt.2015.313. ［17］ Lan F, Yang Y, Han J, et al. Sulforaphane reverses chemoresistance to temozolomide in glioblastoma cells by NFκBdependent pathway downregulating MGMT expression［J］. Int J Oncol, 2016, 48(2): 559568. DOI: 10.3892/ijo.2015.3271. ［18］ Soda Y, Marumoto T, FriedmannMorvinski D, et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells［J］. Proc Natl Acad Sci USA, 2011, 108(11): 42744280. DOI: 10.1073/pnas.1016030108. ［19］ Wang Y, Xing D, Zhao M, et al. The role of a single angiogenesis inhibitor in the treatment of recurrent glioblastoma multiforme: a metaanalysis and systematic review［J］. PLoS One, 2016, 11(3): e0152170. DOI: 10.1371/journal.pone.0152170. ［20］ Lassen U, Sorensen M, Gaziel TB, et al. Phase Ⅱ study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme［J］. Anticancer Res, 2013, 33(4): 16571660. ［21］ Taal W, Oosterkamp HM, Walenkamp AM, et al. Singleagent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial［J］. Lancet Oncol, 2014, 15(9): 943953. DOI: 10.1016/S14702045(14)703146. ［22］ Zeng J, See AP, Phallen J, et al. AntiPD1 blockade and stereotactic radiation produce longterm survival in mice with intracranial gliomas［J］. Int J Radiat Oncol Biol Phys, 2013, 86(2): 343349. DOI: 10.1016/j.ijrobp.2012.12.025. ［23］ Carter T, Shaw H, CohnBrown D, et al. Ipilimumab and bevacizumab in glioblastoma［J］. Clin Oncol (R Coll Radiol), 2016, 28(10): 622626. DOI: 10.1016/j.clon.2016.04.042. ［24］ Müller K, Henke G, Pietschmann S, et al. Reirradiation or reoperation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed highgrade gliomas by means of a new prognostic model［J］. J Neurooncol, 2015, 124(2): 325332. DOI: 10.1007/s1106001518448. ［25］ Akasaki Y, Kikuchi T, Homma S, et al. Phase Ⅰ/Ⅱ trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma［J］. Cancer Immunol Immunother, 2016, 65(12): 14991509. DOI: 10.1007/s0026201619057. ［26］ Giladi M, Schneiderman RS, Voloshin T, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells［J］. Sci Rep, 2015, 5: 18046. DOI: 10.1038/srep18046. ［27］ Stupp R, Wong ET, Kanner AA, et al. NovoTTF100A versus physician′s choice chemotherapy in recurrent glioblastoma: a randomised phase Ⅲ trial of a novel treatment modality［J］. Eur J Cancer, 2012, 48(14): 21922202. DOI: 10.1016/j.ejca.2012.04.011. ［28］ Mrugala MM, Engelhard HH, Dinh Tran D, et al. Clinical practice experience with NovoTTF100ATM system for glioblastoma: the patient registry dataset (PRiDe)［J］. Semin Oncol, 2014, 41 Suppl 6: S4S13. DOI: 10.1053/j.seminoncol.2014.09.010.

[1]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[2]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[3]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[4]	杨丽蓉, 王羽丰. 预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[5]	马培晗, 张灵敏, 路宁, 张明鑫. 麻醉对肝细胞癌复发转移的影响[J]. 国际肿瘤学杂志, 2023, 50(2): 117-121.
[6]	段传菊, 陈真云, 李晓红, 牛洪朋, 李秀敏. 复发宫颈癌免疫治疗1例[J]. 国际肿瘤学杂志, 2023, 50(12): 766-768.
[7]	张露, 周菊英, 马辰莺, 林州. 复发转移性宫颈癌免疫治疗相关进展[J]. 国际肿瘤学杂志, 2022, 49(9): 517-520.
[8]	吴浦嫄, 祁亮, 王涛, 史敏科, 孙雨薇, 王立峰, 刘宝瑞, 闫婧, 任伟. 基于高频复发区改良临床靶区的术后放疗在食管鳞状细胞癌中的疗效研究[J]. 国际肿瘤学杂志, 2022, 49(8): 464-472.
[9]	彭琛, 谢印通, 张昕, 谢鹏. 宫颈癌维持治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(7): 430-435.
[10]	肖楠, 孙鹏飞. 氧化应激在胶质瘤放化疗敏感性中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 357-361.
[11]	高珊, 陆敏秋, 石磊, 褚彬, 房立娟, 项秋晴, 王宇彤, 丁月华, 鲍立. 伊沙佐米联合方案治疗复发/难治多发性骨髓瘤的疗效和安全性分析[J]. 国际肿瘤学杂志, 2022, 49(5): 286-291.
[12]	朱一硕, 崔玉洁, 刘崎, 李军, 范月超. 脑胶质瘤患者术后早期复发危险因素分析及预测模型构建[J]. 国际肿瘤学杂志, 2022, 49(2): 79-83.
[13]	鲁历历, 孙鹏飞, 叶斌强. 放化疗联合盐酸安罗替尼治疗复发性子宫内膜癌1例[J]. 国际肿瘤学杂志, 2022, 49(12): 766-768.
[14]	孔春禹, 孙鹏飞. SLC7A11与胶质瘤[J]. 国际肿瘤学杂志, 2022, 49(10): 604-607.
[15]	郭世豪, 任叶青, 郭庚. 脑胶质瘤血管生成拟态分子机制[J]. 国际肿瘤学杂志, 2021, 48(6): 362-365.